$ cat ./records/who-grants-prequalification-to-r21-matrix-m-the-second-malaria-va-2023.txt
WHO grants prequalification to R21/Matrix-M — the second malaria vaccine to achieve global procurement status
[RECORD.TXT] · cat --full
The World Health Organization awarded prequalification status to R21/Matrix-M on December 21, 2023 — making it only the second malaria vaccine in history to achieve this standing, alongside Gates-funded RTS,S. WHO prequalification enabled Gavi, UNICEF, and national health ministries to procure the vaccine at scale through multilateral channels. With two prequalified malaria vaccines now available for the first time, the global malaria community gained enough combined production capacity to begin immunising tens of millions of African children annually — a crucial threshold for achieving meaningful population-level protection.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation and UNHCR published global best-practice guidelines for sustainable refugee camp sanitation
Next →
R21/Matrix-M malaria vaccine receives first national regulatory approval — in Ghana
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.